Who owns OVID?
Institutional ownership of Ovid Therapeutics Inc. from Form 13F, Q2 2026
131 institutional managers reported holding Ovid Therapeutics Inc. (OVID) in Form 13F filings for Q2 2026, with 147,020,696 shares worth $396M. The largest reported holder was Jupiter Topco LLC. Managers that filed both quarters added a net 31,927,344 shares (+33.8%). 46 opened new positions and 18 sold out.
- Funds holding
- 131
- Value held
- $396M
- New / sold out
- 46 / 18
- Net shares, same filers
- +33.8%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of OVID
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Jupiter Topco LLC | $55.9M | 14.1% | 20,741,234 | First report |
| Eventide Asset Management, LLC | $31.8M | 8.0% | 11,812,241 | Added |
| BlackRock, Inc. | $29.1M | 7.4% | 10,823,480 | Added |
| Ra Capital Management, L.p. | $28.2M | 7.1% | 10,500,968 | Trimmed |
| Affinity Asset Advisors, LLC | $27.3M | 6.9% | 10,144,562 | Trimmed |
| State Street Corp | $21.3M | 5.4% | 7,900,765 | Added |
| Vanguard Capital Management LLC | $20.9M | 5.3% | 7,760,114 | Added |
| ADAR1 Capital Management, LLC | $20.0M | 5.0% | 7,417,479 | Added |
| Balyasny Asset Management L.P. | $18.1M | 4.6% | 6,719,076 | Added |
| Adage Capital Partners GP, L.l.c. | $16.6M | 4.2% | 6,163,781 | Unchanged |
| Federated Hermes, Inc. | $16.0M | 4.0% | 5,951,666 | Added |
| Braidwell LP | $15.9M | 4.0% | 5,919,464 | New |
| Geode Capital Management, LLC | $11.0M | 2.8% | 4,072,653 | Added |
| Silverarc Capital Management, LLC | $8.3M | 2.1% | 3,101,129 | Added |
| Stempoint Capital LP | $6.5M | 1.6% | 2,417,283 | New |
| Ikarian Capital, LLC | $6.1M | 1.5% | 2,269,704 | Trimmed |
| Point72 Asset Management, L.P. | $5.2M | 1.3% | 1,945,727 | Added |
| Sphera Funds Management LTD. | $3.6M | 0.9% | 1,353,000 | Trimmed |
| Northern Trust Corp | $3.4M | 0.8% | 1,246,139 | Added |
| Vanguard Fiduciary Trust Co | $3.1M | 0.8% | 1,140,753 | Added |
| Propel Bio Management, LLC | $3.0M | 0.8% | 1,115,538 | Added |
| Rosalind Advisors, Inc. | $3.0M | 0.8% | 1,107,994 | Unchanged |
| Vanguard Portfolio Management LLC | $2.8M | 0.7% | 1,030,943 | New |
| Sio Capital Management, LLC | $2.7M | 0.7% | 1,005,334 | Trimmed |
| Ensign Peak Advisors, Inc | $2.7M | 0.7% | 988,084 | New |
Share of 13F holdings is each fund's shares as a share of the 147,020,696 OVID shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- BlackRock, Inc. Added+$25.0M
- State Street Corp Added+$19.9M
- Braidwell LP New+$15.9M
- ADAR1 Capital Management, LLC Added+$7.7M
- Geode Capital Management, LLC Added+$7.4M
- Vanguard Capital Management LLC Added+$6.7M
- Stempoint Capital LP New+$6.5M
- Federated Hermes, Inc. Added+$6.4M
- Silverarc Capital Management, LLC Added+$5.7M
- Eventide Asset Management, LLC Added+$5.1M
Biggest sellers in Q2 2026
- Saturn V Capital Management LP Trimmed-$9.4M
- Ally Bridge Group (NY) LLC Trimmed-$5.9M
- Susquehanna International Group, LLP Trimmed-$5.0M
- Blue Owl Capital Holdings LP Sold out-$4.2M
- Millennium Management LLC Trimmed-$3.9M
- Renaissance Technologies LLC Trimmed-$2.7M
- Marshall Wace, LLP Sold out-$2.0M
- Ikarian Capital, LLC Trimmed-$1.7M
- Jane Street Group, LLC Sold out-$1.6M
- Affinity Asset Advisors, LLC Trimmed-$1.3M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $136M and sold $47.9M; 33 added and 27 trimmed.
Schedule 13D and 13G filings on OVID
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-07-29BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2026-05-15EVENTIDE ASSET MANAGEMENT, LLC SCHEDULE 13G filed by Ovid Therapeutics Inc.Schedule 13G
- 2026-05-15BALYASNY ASSET MANAGEMENT L.P. SCHEDULE 13G filed by Ovid Therapeutics Inc.Schedule 13G
- 2026-01-08FEDERATED HERMES, INC. SCHEDULE 13G filed by Ovid Therapeutics Inc.Schedule 13G
- 2026-01-05Point72 Asset Management, L.P. SCHEDULE 13G filed by Ovid Therapeutics Inc.Schedule 13G
- 2025-12-18RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G filed by Ovid Therapeutics Inc.Schedule 13G
- 2025-12-08JANUS HENDERSON GROUP PLC SCHEDULE 13G filed by Ovid Therapeutics Inc.Schedule 13G
Questions about OVID ownership
- Who owns OVID stock?
- 131 institutional investment managers reported OVID positions in their Form 13F filings for Q2 2026, holding 147,020,696 shares worth $396M in total. Jupiter Topco LLC reported the largest position.
- Are funds buying or selling OVID?
- In Q2 2026, 46 managers opened new OVID positions, 33 added, 27 trimmed and 18 sold out. Managers that filed in both quarters added a net 31,927,344 shares.
- How current is this OVID institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to OVID by CUSIP. Options are left out. OVID news and filings · OVID insider trades · Top funds